Chronix Biomedical
The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
Oncocyte to Acquire Chronix Biomedical
The move will add Chronix's proprietary technology for blood-based immune therapy monitoring and transplant rejection testing to Oncocyte's existing test menu.
Oncocyte, Chronix Enter Licensing, Collaboration Agreement for Liquid Biopsy Technology
Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.
The test analyzes circulating cell-free DNA to gauge whether the patient is at high risk for prostate cancer and should go on to receive a biopsy.
Researchers Find Plasma Tumor Marker in Canine Indicating Metastasis
NEW YORK (GenomeWeb News) – Similar to human breast cancers, canine mammary tumors are beset by chromosome instability, researchers from Chronix Biomedical and the Institute of Veterinary Medicine at the University of Göttingen in Germany reported in PLOS One yesterday.
Aug 10, 2011
Nov 11, 2010
Sep 20, 2010
Chronix Nabs $1.8M in Series E Funding
Aug 24, 2010
Apr 13, 2010
Chronix, U of Calgary to Develop Mad Cow Test
Jul 21, 2009